Fact-checked by Grok 2 weeks ago

Conjugated estrogens

Conjugated estrogens, commonly known as conjugated equine estrogens (CEE), are a mixture of water-soluble sodium salts of estrogen sulfates derived exclusively from the urine of pregnant mares, primarily comprising estrone sulfate (approximately 50-60%) and equilin sulfate (22-32%), along with lesser amounts of other equine-specific estrogens such as 17α-dihydroequilin sulfate and Δ8-estrone sulfate.^[1]^[2]^[3] These compounds are hydrolyzed in the body to active unconjugated estrogens, enabling oral bioavailability for hormone replacement therapy to alleviate menopausal vasomotor symptoms like hot flashes, vaginal atrophy, and associated sleep disturbances.^[4]^[5]^[6] Introduced commercially as Premarin in the early 1940s following extraction advancements in the late 1930s, conjugated estrogens became the dominant form of estrogen therapy due to their stability and efficacy in clinical trials demonstrating relief of estrogen deficiency symptoms.^[7]^[8] Unlike synthetic or bioidentical estrogens, their complex equine-derived profile includes unique components like equilin, which contribute to distinct pharmacokinetic properties, including rapid absorption and hepatic first-pass conjugation.^[9]^[10] Clinically, they have been employed for osteoporosis prevention and, historically, in combination with progestins for endometrial protection, though post-2002 Women's Health Initiative findings highlighted elevated risks of breast cancer, stroke, and venous thrombosis with combined CEE-medroxyprogesterone acetate regimens in older postmenopausal women, prompting reevaluation of benefits versus harms on a case-by-case basis.^[11]^[12]^[13] CEE monotherapy, however, showed no increased breast cancer risk and potential cardiovascular event reduction compared to certain synthetic alternatives in some observational data, underscoring variability in estrogen formulations' causal effects on thrombosis and neoplasia.^[14]^[10] These therapies remain prescribed judiciously, balancing empirical symptom relief against documented adverse events informed by large-scale trials rather than anecdotal or institutionally biased narratives.^[15]^[5]

Medical Applications

Primary Indications

Conjugated estrogens are approved for the treatment of moderate to severe vasomotor symptoms associated with menopause, such as hot flashes and night sweats.^[4] They are also indicated for moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, including dryness, irritation, and dyspareunia.^[4] In addition, conjugated estrogens serve to prevent postmenopausal osteoporosis in women at significant risk for whom non-estrogen medications are not suitable.^[4] For conditions involving estrogen deficiency, conjugated estrogens treat hypoestrogenism resulting from female hypogonadism, castration, or primary ovarian failure, aiming to alleviate associated symptoms like amenorrhea and infertility.^[4] They are used short-term for abnormal uterine bleeding due to hormonal imbalance after ruling out malignancy.^[16] In oncology, conjugated estrogens provide palliation for advanced androgen-dependent prostate carcinoma, historically suppressing tumor growth through estrogen-mediated androgen suppression, though use has declined due to cardiovascular risks observed in trials.^[4] They are similarly indicated for palliation of metastatic breast cancer in select men and women.^[4] Off-label, conjugated estrogens have been employed in feminizing hormone therapy for transgender women to promote secondary female characteristics, though guidelines increasingly favor bioidentical estradiol over conjugated forms due to higher thrombosis risk and variable pharmacokinetics.^[17] Empirical data from small cohorts show breast development and fat redistribution, but long-term outcomes remain limited compared to approved estrogens.^[18]

Clinical Efficacy Evidence

Conjugated estrogens effectively alleviate vasomotor symptoms in postmenopausal women, with randomized controlled trials demonstrating substantial reductions in hot flash frequency and severity. In one double-blind study, conjugated equine estrogens led to an 80% decrease in mean daily hot flash frequency among treated participants compared to baseline levels. ^[19] A systematic review of clinical practice guidelines and trial data further confirms that conjugated estrogens provide comparable efficacy to other estrogen formulations, achieving reductions in hot flash episodes of 75-90% in responsive patients. ^[20] Clinical evidence also supports conjugated estrogens in preserving bone mineral density and mitigating fracture risk. The Women's Health Initiative randomized trial reported that conjugated equine estrogens combined with progestin increased bone mineral density by 3.7% at the hip and 3.3% at the spine after three years, alongside a 33% relative reduction in hip fractures and a 34% reduction in vertebral fractures among healthy postmenopausal women. ^[21] Earlier randomized studies similarly showed that estrogen therapy, including conjugated forms, maintained or enhanced bone density at multiple skeletal sites, correlating with lowered osteoporotic fracture incidence in observational follow-up data from treated cohorts. ^[22] For genitourinary symptoms associated with estrogen deficiency, conjugated estrogens promote vaginal tissue restoration, as evidenced by improvements in symptom scores and cytological indices. Trials indicate that systemic administration results in increased vaginal maturation values and reduced pH, alleviating dryness and atrophy through epithelial proliferation and glycogen deposition. ^[23] These histological changes, observed via maturation index assessments, align with patient-reported relief in dyspareunia and irritation, supporting causal efficacy in reversing hypoestrogenic vaginal changes. ^[24]

Available Formulations

Conjugated estrogens are primarily available as oral tablets under the brand name Premarin, in strengths of 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg per tablet, with typical dosing ranging from 0.3 mg to 1.25 mg administered once daily.^[25]^[26] Generic versions of conjugated estrogens tablets USP are also marketed in similar strengths.^[27] These oral formulations release conjugated estrogens that are well absorbed from the gastrointestinal tract but undergo extensive first-pass metabolism in the liver, converting sulfates to unconjugated forms and producing metabolites like estrone and equilin.^[28] Vaginal cream formulations, such as Premarin Vaginal Cream containing 0.625 mg of conjugated estrogens per gram, are applied intravaginally using an applicator, with common regimens including 0.5 g once daily for the first 1-2 weeks followed by twice-weekly maintenance or cyclic dosing adjusted to 0.5 g two to three times per week.^[29]^[30] This route provides localized delivery with reduced systemic absorption compared to oral administration, minimizing hepatic first-pass effects.^[28] Injectable forms include Premarin Intravenous powder for reconstitution, providing 25 mg per vial of conjugated estrogens for intravenous administration, typically diluted and infused over 20-30 minutes for short-term use.^[31]^[32] This parenteral route bypasses gastrointestinal absorption and first-pass metabolism, achieving rapid peak plasma levels.^[31] Combination products pair conjugated estrogens with progestins for specific regimens, such as Prempro tablets (e.g., 0.625 mg conjugated estrogens with 2.5 mg or 5 mg medroxyprogesterone acetate daily) or Premphase (0.625 mg conjugated estrogens alone for days 1-14, followed by 0.625 mg conjugated estrogens plus 5 mg medroxyprogesterone acetate for days 15-28).^[33]^[34] These maintain the oral bioavailability profile of the estrogen component while incorporating sequential or continuous progestin dosing.^[28]

Safety and Risks

Contraindications

Conjugated estrogens are contraindicated in patients with a known or suspected pregnancy, as exposure during pregnancy is associated with increased risks of congenital anomalies and other fetal harms, supported by empirical data from animal teratology studies and limited human case reports indicating potential for feminization of male fetuses and vaginal cancer in exposed female offspring.^[25]^[35] They are also contraindicated in individuals with undiagnosed abnormal vaginal bleeding, which requires evaluation to exclude underlying endometrial hyperplasia or malignancy before initiating therapy, as estrogens can exacerbate unaddressed neoplastic conditions.^[25]^[27] Therapy is absolutely contraindicated in patients with known or suspected estrogen-dependent neoplasia, including breast cancer and endometrial cancer, due to causal evidence from epidemiological studies linking exogenous estrogens to tumor progression in hormone-sensitive tissues.^[25]^[28] Active or recent arterial thromboembolic events, such as stroke or myocardial infarction, or venous thromboembolic disorders like deep vein thrombosis or pulmonary embolism, represent contraindications, as oral conjugated estrogens elevate thrombosis risk through mechanisms including reduced antithrombin III activity, increased factor VII, and prothrombin activation, with relative risks of 1.3-3 fold for venous thromboembolism observed in postmenopausal hormone therapy cohorts.^[25]^[36]^[27] Additional absolute contraindications include known thrombophilic disorders (e.g., protein C, protein S, or antithrombin deficiency), which amplify the prothrombotic effects of estrogens, and active liver dysfunction or disease, as impaired hepatic metabolism heightens estrogen accumulation and associated cardiovascular risks, per FDA black-box warnings on cardiovascular disorders.^[25]^[37]^[28] Hypersensitivity to conjugated estrogens or any component of the formulation is likewise a contraindication to avoid anaphylactic reactions.^[25] Relative contraindications may apply in cases of severe hypertriglyceridemia or migraine with aura, where estrogen therapy could precipitate pancreatitis or cerebrovascular events, though these warrant individualized risk assessment rather than absolute prohibition.^[25]

Common and Serious Adverse Effects

Common adverse effects of conjugated estrogens, occurring in 5% or more of users in clinical trials, include headache (incidence 13-14%), breast pain (7-12%), and abdominal pain (6-11%).^[25] Other frequently reported effects encompass nausea (3-5% to 6-12% across studies), flatulence (4-6%), and vaginal hemorrhage or spotting (2-13%), often resolving with continued use or dose adjustment.^[25] ^[38] These gastrointestinal and breast-related symptoms arise from estrogen's influence on tissue proliferation and fluid retention, with incidences derived from placebo-controlled trials involving postmenopausal women.^[25] Serious adverse effects include an elevated risk of venous thromboembolism (VTE), with estrogen-alone therapy showing 30 events per 10,000 women-years versus 22 in placebo users, yielding a relative risk of approximately 1.4-fold.^[25] This risk is dose- and route-dependent, higher with oral administration due to first-pass liver effects on clotting factors, and peaks early in treatment.^[36] Stroke risk increases modestly, at 45 versus 33 per 10,000 women-years in estrogen-alone users aged 50-79.^[25] Unopposed conjugated estrogens (without progestin) cause endometrial hyperplasia in up to 20% of postmenopausal users after one year at 0.625 mg daily, a dose-dependent effect mitigated to under 1% with progestin co-administration.^[39] Long-term use elevates this risk 2- to 12-fold overall, and up to 15- to 24-fold after 5-10 years.^[25] ^[39] Additional serious associations include gallbladder disease requiring surgery, with a 2- to 4-fold increased risk linked to estrogen-induced cholesterol supersaturation in bile.^[25] These risks inform individualized assessments, particularly in women with predisposing factors like age over 60 or obesity, where absolute event rates remain low but causal links are supported by randomized trial data.^[25]^[40]

Overdose and Toxicity

Overdosage of conjugated estrogens, as with other estrogen formulations, primarily results in symptoms of acute hyperestrogenism, including nausea, vomiting, breast tenderness, abdominal pain, drowsiness, fatigue, and withdrawal bleeding in women.^[41] These effects arise from excessive estrogen receptor activation and are typically self-limiting without intervention beyond drug cessation.^[13] No specific antidote exists for conjugated estrogen overdose; treatment is supportive and consists of immediate discontinuation of the medication, gastric decontamination if ingestion was recent, and symptomatic management such as antiemetics for gastrointestinal distress or monitoring for fluid/electrolyte imbalances.^[13]^[42] Patients should be observed for resolution of symptoms, which generally occur within days as the drug's half-life allows for clearance.^[41] Conjugated estrogens exhibit low acute toxicity in humans, with no documented fatalities from overdose despite therapeutic doses ranging from 0.3 to 1.25 mg daily; symptomatic cases have been reported at multiples exceeding standard dosing, but thresholds for severe effects remain undefined in clinical literature.^[27] In preclinical studies, oral non-lethal doses reached 4000 mg/kg in mice and rats, indicating a wide therapeutic index compared to typical human exposures.^[43] This contrasts with chronic exposure risks, as acute overdose effects are reversible upon withdrawal without the cumulative oncogenic or thrombotic potential observed in prolonged use.^[13]

Pharmacology

Pharmacodynamics

Conjugated estrogens comprise a mixture of sulfate-conjugated forms of equine estrogens, primarily estrone sulfate and equilin sulfate, which act as prodrugs hydrolyzed by endogenous sulfatases to their biologically active unconjugated counterparts. These active estrogens bind agonistically to estrogen receptors α (ERα) and β (ERβ), nuclear receptors that, upon ligand binding, undergo conformational changes, dimerize, and translocate to the nucleus to interact with estrogen response elements (ERE) on DNA, thereby modulating transcription of target genes. This genomic mechanism drives increased synthesis of DNA, RNA, and proteins in estrogen-responsive tissues.^[44] The pharmacodynamic profile includes antigonadotropic effects, wherein elevated estrogen levels exert negative feedback on the hypothalamic-pituitary axis, suppressing gonadotropin-releasing hormone (GnRH) secretion and consequently reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) release from the pituitary gland. This suppression mimics the regulatory dynamics of endogenous estrogens in premenopausal cycles, inhibiting ovarian follicle development and ovulation at sufficient doses.^[44]^[45] Tissue-selective actions stem from varying ERα/ERβ ratios and co-regulator availability across cell types. In bone, ER activation predominantly inhibits osteoclast activity and resorption while promoting osteoblast function, thereby maintaining bone mineral density. Vascular effects involve ER-mediated endothelial nitric oxide synthase (eNOS) upregulation, enhancing vasodilation and stabilizing vasomotor tone. In the liver, ER signaling induces synthesis of prothrombotic proteins, including factors VII, VIII, X, fibrinogen, and plasminogen activator inhibitor-1 (PAI-1), which contribute to a hypercoagulable state.^[44]^[46]^[47]^[36]

Pharmacokinetics

Conjugated estrogens, being water-soluble, are well absorbed from the gastrointestinal tract after oral administration, with the tablet formulation designed for slow release over several hours. Peak plasma concentrations (C_max) for conjugated total estrone and equilin occur at approximately 5-8 hours (t_max 5.6-8.2 hours following 0.625-1.25 mg doses), while unconjugated forms peak later at 7-10 hours. The overall oral bioavailability of estrogens in this preparation is low, ranging from 2-10%, primarily due to extensive first-pass hepatic metabolism and enterohepatic recirculation, which contributes to prolonged exposure.^[4]^[48]^[49] Following absorption, conjugated estrogens undergo hydrolysis by tissue sulfatases to yield free estrogens such as estrone and equilin, which are distributed widely, including to estrogen target organs, and bound extensively to sex hormone-binding globulin (SHBG) and albumin. Metabolism mirrors that of endogenous estrogens, occurring mainly in the liver via cytochrome P450 enzymes (including CYP3A4), with interconversion between estradiol and estrone, followed by conjugation with sulfate or glucuronide groups; this process supports significant enterohepatic recirculation, enhancing duration of action. Unconjugated estrogens clear faster from plasma than their conjugated counterparts.^[4]^[44]^[50] Elimination of conjugated estrogens and their metabolites occurs primarily via urinary excretion as glucuronide and sulfate conjugates of estradiol, estrone, and estriol, with lesser fecal elimination through biliary secretion. Half-lives vary by component: baseline-adjusted unconjugated estrone approximately 20 hours, conjugated total estrone 15-18 hours, and equilin forms 10-13 hours, yielding a median of about 17 hours overall; steady-state plasma levels are typically reached after 5-7 days of continuous dosing. Clearance rates are around 600-700 L/m²/day for estrogens.^[4]^[44]^[51]

Chemistry and Production

Chemical Composition

Conjugated estrogens comprise a complex mixture of sulfate esters of at least 10 steroidal estrogens, primarily sodium salts that enhance water solubility and stability compared to unconjugated forms. The United States Pharmacopeia (USP) specifies that sodium estrone sulfate constitutes 52–62% and sodium equilin sulfate 22–30% of the total, with their combined content ranging from 80–88%.^[44]^[52] Minor components include conjugates of 17α-dihydroequilin (about 13–15%), equilenin, and others such as δ8,9-dehydroestrone sulfate.^[44] The USP monograph mandates quantification of these 10 key steroidal components via high-performance liquid chromatography (HPLC) to verify batch potency and consistency, ensuring total conjugated estrogens content meets labeled specifications.^[52]^[2] Unlike bioidentical estrogens such as 17β-estradiol, which structurally mirrors the primary human ovarian hormone with a Δ4-3-keto configuration and 17β-hydroxyl group, equine-derived conjugated estrogens incorporate non-human variants. Equilin features an additional double bond at positions 6–7 in ring B, while 17α-dihydroequilin exhibits an α-hydroxyl at carbon 17, altering estrogen receptor binding kinetics and tissue-specific effects relative to human estrogens.^[53]^[54] These structural deviations contribute to a broader, heterogeneous estrogenic profile distinct from synthetic or purely human-sourced formulations.^[10]

Sourcing from Pregnant Mare Urine

Conjugated estrogens are extracted from the urine of pregnant mares, collected on specialized farms primarily in Canada and parts of the United States, where herds of mares are maintained under contract with pharmaceutical producers such as Pfizer.^[55] These pregnant mare urine (PMU) operations leverage the elevated estrogen levels in mare urine during the third trimester, when conjugated equine estrogens reach peak concentrations, enabling efficient large-scale harvesting through automated collection systems attached to stalls.^[56] The industrial process begins with filtration of the raw urine to eliminate particulates and debris, followed by acidification and precipitation steps to concentrate the water-soluble conjugated estrogens, which are then purified via solvent extraction or solid-phase methods to yield a mixture dominated by estrone sulfate and equilin sulfate.^[57] ^[58] This patented approach, developed by Wyeth in the 1940s through innovations in isolation techniques, facilitated scalable production post-World War II as demand for hormone therapies grew, allowing output sufficient for commercial formulations like Premarin without reliance on labor-intensive synthesis.^[59] The PMU-derived method remains predominant over fully synthetic alternatives due to its cost-effectiveness in producing the specific multi-component equine estrogen profile, which has supported consistent therapeutic outcomes in clinical use since the 1940s, despite availability of synthetic versions.^[60]^[61]

Historical Context

Development and Approval

Conjugated estrogens, derived from the urine of pregnant mares, emerged from early 20th-century research on female sex hormones. In 1923, Edgar Allen and Edward Doisy demonstrated the existence of an ovarian hormone capable of inducing estrus in rodents, laying foundational work for estrogen isolation.^[62] By 1929, Doisy had crystallized estrone from sow ovaries, advancing purification techniques that informed subsequent developments in equine-derived formulations.^[63] Wyeth Laboratories (later Wyeth-Ayerst) began extracting conjugated equine estrogens from pregnant mare urine in the late 1930s, leveraging the high estrogen content for therapeutic potential.^[7] Premarin, the branded formulation of conjugated estrogens, was commercialized by Wyeth in 1941 as tablets for menopausal symptom relief, following demonstration of safety under pre-1962 FDA standards that did not require efficacy trials.^[7] Full FDA approval for marketing came in May 1942, initially for vasomotor symptoms and related conditions associated with menopause.^[7] ^[64] By the 1980s, accumulating observational data on reduced fracture rates prompted expanded indications; in 1986, clinical trials confirmed efficacy for osteoporosis prevention in postmenopausal women, leading to formal FDA endorsement for prophylaxis against bone loss.^[44] Following the 2002 Women's Health Initiative (WHI) trial results highlighting cardiovascular and cancer risks with combined hormone therapy, the FDA mandated label updates for estrogen products, including Premarin, to incorporate these findings.^[28] Wyeth proactively revised Premarin labeling in 2003 to include WHI-derived risk data, such as increased stroke incidence, while affirming continued approval for short-term menopausal symptom management in women without contraindications.^[65] Subsequent supplements through the 2000s maintained these approvals with enhanced warnings, balancing empirical risk evidence against benefits for vasomotor and urogenital symptoms.^[66]

Key Milestones in Usage

Conjugated estrogens, primarily marketed as Premarin, saw initial widespread adoption in the United States following its approval for menopausal symptoms in 1942, with prescription volumes surging in the 1960s as estrogen therapy gained popularity for alleviating vasomotor symptoms and promoting vitality.^[7] By the mid-1960s to mid-1970s, estrogen sales had doubled or tripled annually, driven by clinical observations and marketing emphasizing long-term use beyond acute symptoms.^[7] This trend accelerated through the 1990s, culminating in Premarin becoming the most prescribed drug in the U.S. by 1992, with annual prescriptions reaching approximately 46 million by 2000 and sales exceeding $1 billion in 1997, reflecting use among an estimated 40% of postmenopausal women for hormone replacement therapy (HRT).^[67]^[68] The 2002 publication of preliminary results from the Women's Health Initiative (WHI), which halted the estrogen-progestin arm due to observed risks, triggered a precipitous decline in HRT prescriptions, including conjugated estrogens. U.S. menopausal hormone therapy (MHT) prevalence dropped from 29% in 2001 to 10-11% by 2005, with overall use falling to 4.7% by the early 2020s, particularly among women aged 50-59.^[69] This shift mirrored global patterns, as guidelines worldwide echoed caution, reducing prescriptions by up to 70% in some regions post-2003.^[70] Reanalyses of WHI data in the 2010s, emphasizing the "timing hypothesis," prompted a nuanced resurgence in targeted use for early menopausal women, highlighting reduced mortality and cardiovascular benefits when initiated within 10 years of menopause onset or before age 60.^[71] By the 2020s, prescription patterns stabilized at lower levels but incorporated individualized approaches for symptomatic relief, with organizations like the North American Menopause Society affirming in 2022 that short-term hormone therapy benefits outweigh risks for healthy women under 60 treating vasomotor symptoms or genitourinary issues.^[72] This guideline evolution tied to empirical subgroup findings has supported selective global adoption, particularly for early interventions, amid sustained overall declines from peak usage eras.^[73]

Controversies and Debates

Women's Health Initiative Study and Interpretations

The Women's Health Initiative (WHI), a large-scale randomized controlled trial initiated in 1993, included two hormone therapy arms evaluating conjugated equine estrogens (CEE) in postmenopausal women aged 50-79. The combined CEE (0.625 mg/day) plus medroxyprogesterone acetate (MPA, 2.5 mg/day) arm enrolled 16,608 women with intact uteri, with intervention halted after a median 5.2 years in July 2002 due to excess risks exceeding benefits. Principal findings reported a hazard ratio (HR) of 1.26 (95% CI, 1.00-1.59) for invasive breast cancer, translating to 8 additional cases per 10,000 women per year, alongside an HR of 1.29 (95% CI, 1.02-1.63) for coronary heart disease (CHD) events, or 7 additional events per 10,000 women per year; stroke and pulmonary embolism risks also increased modestly (HR 1.41 and 2.13, respectively).^[74]^[75] Absolute risks remained small overall, with no significant mortality increase during the trial period.^[76] The CEE-alone arm, involving 10,739 hysterectomized women, continued to a median 7.1 years before termination in March 2004 for futility regarding CHD prevention. Results showed no elevation in breast cancer risk (HR 0.77, 95% CI, 0.59-1.01, with 7 fewer cases per 10,000 women per year), neutral CHD effects (HR 0.91, 95% CI, 0.75-1.12), increased stroke risk (HR 1.39, 95% CI, 1.10-1.77), and reduced hip fracture incidence (HR 0.66, 95% CI, 0.45-0.98).^[23] Unlike the combined arm, estrogen monotherapy did not demonstrate overall harms outweighing benefits, though subgroup analyses were limited initially.^[77] Subsequent reanalyses and long-term follow-up (median 13-18 years) highlighted age-specific effects, revealing cardiovascular disease (CVD) benefits for women under 60 at initiation, particularly in the CEE-alone trial, where cumulative data indicated reduced CHD, myocardial infarction, and all-cause mortality risks (e.g., HR 0.70 for composite CVD outcomes in ages 50-59).^[78]^[79] Meta-analyses incorporating WHI data confirmed CHD risk reduction (odds ratio 0.66) for hormone therapy initiation within 10 years of menopause, contrasting overall trial neutrality.^[80] These findings underscore timing hypotheses, with early initiation potentially conferring vascular protection absent in older cohorts (mean age ~63 years in WHI).^[81] Critiques of the WHI emphasize design limitations undermining generalizability: the cohort's advanced postmenopausal status (average 12-13 years since menopause) and predominant oral administration likely amplified prothrombotic effects via first-pass hepatic metabolism, effects mitigated by transdermal routes or earlier use.^[82]^[76] Observational studies, showing pre-WHI CHD benefits, suffered from confounding by indication and healthy-user bias—favoring adherent, healthier users—yet RCTs like WHI avoided selection bias but enrolled non-representative women distant from perimenopause, where symptom-driven therapy is typical.^[83] Initial interpretations fueled widespread hormone therapy discontinuation, but reanalyses privileging absolute risks and subgroup data reveal overstated alarmism, with no long-term all-cause mortality increase (HR 0.99 for CEE+MPA; HR 1.02 for CEE-alone after 18 years).^[84]^[85]

Animal Welfare in Production

Pregnant mares used in conjugated estrogens production are typically housed in tie stalls during the urine collection phase, which spans approximately six months from around 120 days of gestation until foaling, with stall dimensions sized by weight—minimum widths of 4 feet for mares up to 1,300 pounds, 4.5 feet for 1,301–1,700 pounds, and 5 feet for heavier animals—to allow lying down, rising, and limited forward movement.^[86] Urine collection employs lightweight, fitted harnesses rather than invasive catheters, with equipment checked daily for cleanliness and fit, and removed if causing discomfort; no restraints on tails, pasterns, or legs are permitted, and collection halts for any ill or disabled mares.^[86] Veterinary oversight is mandatory via herd health programs, including vaccinations, parasite control, and body condition scoring maintained at 5–7 on a 9-point scale, with adequate bedding, feeding, and water provision (4–12 gallons daily per mare).^[86] Post-collection, mares receive turnout in areas providing at least 1,000 square feet per animal, with shelter and drainage.^[86] The American Association of Equine Practitioners endorses these practices under the Code of Practice for the Care and Handling of Horses on PMU Ranches, affirming that they prevent abuse or neglect when followed, with standards aligned to broader equine welfare norms.^[87] In the 2000s, Pfizer-contracted farms underwent monthly audits by trained field auditors using the FARMS system, alongside twice-seasonal veterinary herd health reviews, confirming compliance with nutrition (per NRC 2007 guidelines), biosecurity, and farriery (minimum twice-yearly hoof care, with monthly monitoring).^[88] These inspections, cross-referenced with provincial regulations like Canada's Health of Animals Act, found no deviations warranting systemic abuse claims, which often stem from unverified activist narratives exceeding typical agricultural horse management.^[88] Foals are weaned at a minimum of three months (typically four or more), in sheltered areas, with transport limited to 12 hours followed by rest; sales are restricted until after September 1 to ensure maturity.^[86] Historically, many PMU foals entered auctions, with a portion directed to slaughter markets amid high production volumes peaking at 40,000–50,000 annually in the U.S. and Canada, though colts faced higher risks due to market preferences.^[89] Industry initiatives, such as NAERIC's Advantage program and the Equine Placement Fund, have since facilitated adoption or placement of over 30,000 PMU offspring into productive uses since 2003, mitigating surplus outcomes through targeted marketing and rescues.^[88] Audits indicate foal handling meets equine standards, with no evidence of practices diverging from commercial breeding norms.^[88]

Litigation and Regulatory Actions

Following the publication of the Women's Health Initiative study results in 2002, manufacturers of conjugated estrogens products, such as Wyeth (acquired by Pfizer in 2009), faced numerous class action lawsuits alleging failure to adequately warn consumers about risks including breast cancer and cardiovascular events associated with drugs like Premarin.^[90] Plaintiffs claimed that pre-2002 labeling understated these hazards, leading to claims for compensatory and punitive damages.^[91] While some individual verdicts awarded significant sums, such as $34.3 million against Pfizer in a 2009 Pennsylvania case involving a breast cancer survivor, courts in multiple jurisdictions upheld the adequacy of existing labels prior to the study's findings, dismissing many failure-to-warn claims on the grounds that risks were disclosed based on contemporaneous evidence.^[90] Settlements totaling over $200 million were reached in specific actions, including a California class settlement for Premarin purchasers and smaller funds like $5.2 million in a 2007 case, though these often covered legal fees and provided limited per-claimant payouts after deductions.^[92]^[93] In regulatory responses, the U.S. Food and Drug Administration (FDA) mandated black box warnings on conjugated estrogens labels in 2003, emphasizing increased risks of cardiovascular disorders (including stroke and myocardial infarction), breast cancer, endometrial cancer, and probable dementia when used for menopausal symptom relief or prevention.^[94]^[25] These warnings applied to products like Premarin, requiring the lowest effective dose for the shortest duration and contraindicating use for primary prevention of chronic diseases.^[7] In the 2020s, FDA expert panels revisited menopausal hormone therapy, with a July 2025 panel affirming net benefits for short-term vasomotor symptom management in women under 60 or within 10 years of menopause, despite persistent risks, and recommending a review to potentially refine or remove elements of the boxed warning based on updated risk-benefit data stratified by age, timing, and formulation.^[95]^[96] As of October 2025, the warnings remain in place, with ongoing debates over their chilling effect on appropriate use versus overstatement of absolute risks for select patients.^[97] Internationally, regulatory stances diverge from the U.S. model; the European Medicines Agency and national bodies have imposed stricter limitations on systemic hormone replacement therapy, including conjugated estrogens, with guidelines like the European Code against Cancer (4th edition) advising to limit or avoid HRT due to elevated cancer risks, leading to sharper declines in prescriptions compared to the U.S.^[98] In contrast, U.S. policy prioritizes patient access with robust informed consent and monitoring, reflecting empirical evidence that individualized risk assessment—considering factors like timing of initiation—can justify use despite hazards, whereas European approaches emphasize precautionary restrictions amid similar post-WHI data interpretations.^[99] This variance underscores debates over whether U.S. labeling balances evidence-based caution without unduly restricting symptom relief, while EU frameworks prioritize avoidance to minimize population-level harms.^[100]

Societal and Regulatory Dimensions

Generic Names and Availability

Conjugated estrogens, denoted chemically as a mixture of sulfate esters of estrone, equilin, and other equine estrogens, is the international nonproprietary name (INN) and United States Adopted Name (USAN) for this hormone preparation.^[101] It is also referred to as conjugated equine estrogens (CEEs) to specify its origin from pregnant mare urine.^[102] The primary brand name worldwide is Premarin, manufactured by Pfizer, available in oral tablet, vaginal cream, and injectable forms for indications such as menopausal symptom relief and hypoestrogenism.^[103] No therapeutically equivalent generic versions of Premarin have been approved by the U.S. Food and Drug Administration (FDA), despite the expiration of key composition patents such as U.S. Patent 5,210,081 in the early 2000s, due to difficulties in replicating the exact sulfate profile and demonstrating bioequivalence for this natural mixture.^[104]^[105] Premarin is marketed in numerous countries across North America, Europe, Asia, and other regions, with formulations approved by regulatory bodies including the FDA (since 1942 for certain indications), the European Medicines Agency, and equivalents in Canada, Australia, and Japan.^[106] In the United States, a 30-day supply of Premarin 0.625 mg tablets retails for approximately $277 without insurance, though patient assistance programs and coupons can lower costs to around $99.^[107] Vaginal cream formulations average $458–$568 for a 30-gram tube at full price, with similar discount options available.^[108] Conjugated estrogens requires a prescription in the United States and most developed nations, classified under FDA pregnancy category X due to contraindications in pregnancy and monitored for cardiovascular and oncologic risks.^[4] No over-the-counter forms exist for systemic or topical use, as all estrogen products containing conjugated estrogens demand medical oversight to mitigate adverse effects like thromboembolism.^[101] Supply shortages have been infrequent since 2020, primarily affecting niche formulations rather than core oral products.^[104]

Comparisons to Bioidentical Alternatives

Bioidentical hormones refer to estradiol and progesterone formulations chemically identical to those produced by the human body, available either as FDA-approved products (e.g., transdermal estradiol patches or micronized progesterone capsules) or custom-compounded preparations. Clinical trials and meta-analyses indicate that FDA-approved bioidentical estradiol achieves similar efficacy to conjugated equine estrogens (CEE) in reducing vasomotor symptoms and improving quality of life in menopausal women, with no significant differences in symptom relief rates across randomized controlled trials.^[109]^[110] Regarding safety, transdermal estradiol exhibits a lower venous thromboembolism (VTE) risk compared to oral CEE, attributed to bypassing hepatic first-pass metabolism; observational data from large cohorts report adjusted odds ratios of 0.85 for oral estradiol versus CEE and near-null risk elevation (OR 0.93) for transdermal routes overall. However, for breast cancer, long-term follow-up from the Women's Health Initiative (WHI) demonstrates that CEE alone reduces incidence (HR 0.77 after 20+ years), while evidence for bioidentical estradiol—primarily from smaller or observational studies—shows no superior risk profile and lacks equivalent randomized data. Cardiovascular outcomes similarly lack proof of bioidentical advantage, with guidelines emphasizing that claims of overall safety superiority remain unsubstantiated by large-scale trials.^[111]^[112]^[113] Compounded bioidentical hormones, not subject to FDA oversight, carry heightened risks of inconsistent dosing, contamination, and variable absorption, as documented in adverse event reports linking them to endometrial hyperplasia and other complications; the Endocrine Society and ACOG recommend restricting their use to cases of allergy to FDA-approved ingredients due to absent standardization and quality controls.^[114]^[115]^[116] The North American Menopause Society's 2022 position statement affirms no clear superiority of bioidenticals over FDA-approved CEE for efficacy or safety, prioritizing regulated products with established pharmacokinetics and urging caution against compounded alternatives lacking rigorous data. CEE benefits from decades of longitudinal evidence from trials like WHI and PEPI, providing a more robust basis for risk assessment than the limited randomized datasets for many bioidentical regimens.^[72]^[117] Proponents' marketing of bioidenticals as inherently "safer" or "natural" overlooks CEE's empirical track record and the equine-derived composition's irrelevance to human outcomes, while ignoring compounding variability that can undermine therapeutic consistency.^[118]

References

[1]
[PDF] Premarin Intravenous (conjugated estrogens, USP) for injection ...
conjugated estrogens obtained exclusively from natural sources, occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the ...
[2]
Determining the Consistently Present Steroidal Content with LC-MS
Aug 5, 2015 · Conjugated estrogens, US Pharmacopeia (USP), is a mixture of a substantial number of mostly sulfated estrogens and other steroids with ...
[3]
The History of Estrogen - February 2016 - menoPAUSE Blog
Feb 17, 2016 · Premarin® contained at least ten estrogens, the dominant ones being estrone (50% to 60%) and equilin (22.5% to 32.5%) with less than 5% ...Missing: conjugated | Show results with:conjugated
[4]
[PDF] PREMARIN® (conjugated estrogens tablets, USP) Rx only WARNING
A. Absorption. Conjugated estrogens are water-soluble and are well-absorbed from the gastrointestinal tract after release from the drug formulation. The ...
[5]
Pharmacology of conjugated equine estrogens: efficacy, safety and ...
CEE is most commonly used for the management of early menopausal symptoms such as hot flashes, vaginitis, insomnia, and mood disturbances.Missing: composition | Show results with:composition
[6]
Clinical Opinion: The Biologic and Pharmacologic Principles of ...
Mar 28, 2006 · Unconjugated estrogens (eg, equilin) are absorbed more rapidly than conjugated estrogens (eg, equilin sulfate), but they are soon conjugated by ...
[7]
Estrogens and progestins: background and history, trends in use ...
In 1972, the FDA published a Federal Register notice announcing that a number of estrogen products, including Premarin, had been shown to be effective in the ...
[8]
Premarin - C&EN - American Chemical Society
Jun 20, 2005 · In the 1920s, scientists discovered that estrogens could be extracted from the human placenta and umbilical cord and used therapeutically.
[9]
The History of Estrogen Therapy - PMC - NIH
Jul 4, 2020 · The role of estrogen was first accurately described in Guinea pigs in 1917 by Dr. Papanicolaou. Aim: Here we tell a detailed history of how ...
[10]
Pharmacology of conjugated equine estrogens: Efficacy, safety and ...
Eqn, Δ8-E1 and Δ3-17β-E2 may help prevent cardiovascular and Alzheimer's disease. Abstract. Oral conjugated equine estrogens (CEE) are the most used estrogen ...
[11]
Esterified Estrogens and Conjugated Equine Estrogens and the Risk ...
Oct 6, 2004 · Conjugated equine estrogens contain 10 known biologically active estrogen compounds, as well as others that have yet to be described, which has ...
[12]
Conjugated Equine Estrogen, Esterified Estrogen, Prothrombotic ...
Sep 14, 2006 · Risks and benefits of estrogen plus progestin ... Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.
[13]
Estrogen Therapy - StatPearls - NCBI Bookshelf - NIH
Feb 18, 2025 · Estrogen therapy is a form of hormone replacement therapy used to manage symptoms associated with menopause, including vasomotor symptoms such as hot flashes ...<|separator|>
[14]
Lower Risk of Cardiovascular Events in Postmenopausal Women ...
Objective To compare the relative clinical cardiovascular safety of 2 commonly used oral estrogen drugs—conjugated equine estrogens (CEEs) and estradiol. Design ...
[15]
Hormone Replacement Therapy - StatPearls - NCBI Bookshelf - NIH
Oct 6, 2024 · Vaginal hormone therapies for GSM include estrogen creams (eg, conjugated equine estrogens ... review of risks and benefits. Gynecol Oncol ...
[16]
Premarin - conjugated estrogens (Rx) - Medscape Reference
Prostate Cancer. Palliation only. 1.25-2.5 mg PO q8hr. Abnormal Uterine Bleeding. 25 mg IV/IM; repeated in 6-12 hours PRN or 25 mg IV repeated q4hr for 24 hr ...
[17]
Gender-affirming hormone therapy in the transgender patient
Dec 6, 2024 · Ethinyl estradiol and some conjugated estrogens are no longer recommended in the setting of gender affirmation due to the increased risk of ...
[18]
Overview of feminizing hormone therapy - UCSF Transgender Care
Jun 17, 2016 · The goal of feminizing hormone therapy is the development of female secondary sex characteristics, and suppression/minimization of male secondary sex ...
[19]
Commonly Used Types of Postmenopausal Estrogen for Treatment ...
Apr 7, 2004 · In 1 study, patients using CEE at 0.625 mg/d had a reduction of mean daily frequency of hot flashes by 80%, and patients using CEE at 1.25 mg/d ...
[20]
Postmenopausal Estrogen for Treatment of Hot Flashes: Clinical ...
Apr 7, 2004 · Trial data indicate that CEE and oral and transdermal 17β-estradiol have similar effectiveness in treating hot flashes. Limited numbers of ...<|separator|>
[21]
Effects of Estrogen Plus Progestin on Risk of Fracture and Bone ...
Oct 1, 2003 · Conclusions This study demonstrates that estrogen plus progestin increases BMD and reduces the risk of fracture in healthy postmenopausal women.
[22]
The Effect of Postmenopausal Estrogen Therapy on Bone Density in ...
Oct 14, 1993 · In our study, among women under the age of 75, bone density was higher in the women treated with estrogen. How is that likely to affect the risk ...
[23]
Effects of Conjugated Equine Estrogen in Postmenopausal Women ...
Apr 14, 2004 · The current study suggests that younger women who use CEE may be at reduced risk of CHD but this possible association may be due to chance.
[24]
Effects of vaginal administration of conjugated estrogens tablet on ...
Aug 12, 2020 · The results showed that vaginal administration of conjugated estrogens tablet significantly improved vaginal pH and Vaginal Maturation Value, ...
[25]
[PDF] PREMARIN® (conjugated estrogens) tablets, for oral use
Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks ...
[26]
PREMARIN® (conjugated estrogens) Dosage Forms and Strengths
Tablet Strength. Tablet Shape/Color. Imprint. 0.3 mg. oval/green. PREMARIN 0.3. 0.45 mg. oval/blue. PREMARIN 0.45. 0.625 mg. oval/maroon. PREMARIN
[27]
[PDF] Conjugated Estrogens Tablets USP - Premarin - Pfizer
Approximately 0.2 mg trace solids. All strengths/presentations mentioned in this document might not be available in the market. 3. DOSAGE FORM AND STRENGTH.
[28]
[PDF] Premarin - accessdata.fda.gov
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER. Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures,.
[29]
[PDF] Premarin® Vaginal Cream (Conjugated Estrogens, 0.625 mg/g)
Pregnant Women: Premarin® Vaginal Cream is contraindicated during pregnancy (see CONTRAINDICATIONS). If pregnancy occurs during medication with PREMARIN ...Missing: injectable | Show results with:injectable
[30]
Premarin Vaginal Cream (conjugated estrogens, vaginal) dosing ...
Treats symptom of vulvar and vaginal atrophy due to menopause. 0.5 g intravaginally in a twice-weekly (eg, Monday and Thursday) continuously or in a cyclic ...
[31]
[PDF] Premarin Intravenous - accessdata.fda.gov
Premarin Intravenous is indicated for short-term use only, to provide a rapid and temporary increase in estrogen levels.
[32]
Premarin Injection: Package Insert / Prescribing Info - Drugs.com
Jun 4, 2025 · Premarin Intravenous (conjugated estrogens, USP) for injection contains a mixture of conjugated estrogens obtained exclusively from natural sources.
[33]
Conjugated estrogens and medroxyprogesterone (oral route)
Premphase®: One maroon tablet (0.625 milligrams (mg) conjugated estrogens) once a day on Days 1 to 14, followed by one light-blue tablet (0.625 mg conjugated ...Before Using · Drug Interactions · Side Effects
[34]
Conjugated Estrogens / Medroxyprogesterone Dosage - Drugs.com
May 7, 2025 · Usual Adult Dose for Osteoporosis. 1 tablet orally once a day. Two regimens available, either. Regimen 1: A combined conjugated ...Additional Dosage... · Precautions · Other Comments<|separator|>
[35]
[PDF] 4177966 This label may not be the latest approved by FDA. For ...
PREMARIN should not be used during pregnancy [see Contraindications (4)]. There appears to be little or no increased risk of birth defects in children born ...
[36]
Estrogen and Thrombosis: a Bench to Bedside Review - PMC
It has been well established that estrogen increases the risk of both arterial and venous thrombosis. While estrogen is known to induce a prothrombotic milieu ...
[37]
[PDF] synthetic conjugated estrogens Label - accessdata.fda.gov
Synthetic Conjugated Estrogens, A Vaginal Cream is indicated for use in women only.
[38]
Conjugated Estrogens - Elsevier healthcare hub
Sep 30, 2025 · Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's health ...<|separator|>
[39]
Incidence of endometrial hyperplasia in postmenopausal ... - PubMed
Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens ...Missing: rates | Show results with:rates
[40]
Venous Thrombosis and Conjugated Equine Estrogen in Women ...
Apr 10, 2006 · An early increased VT risk is associated with use of estrogen, especially within the first 2 years, but this risk increase is less than that for estrogen plus ...Missing: endometrial hyperplasia
[41]
[PDF] PREMARIN (conjugated estrogens) Vaginal Cream
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR. DISORDERS, BREAST CANCER and PROBABLE DEMENTIA. 1 INDICATIONS AND USAGE. 1.1 Treatment of Atrophic Vaginitis ...
[42]
[PDF] Premarin®Vaginal Cream - Pfizer
4.9 Overdose There is no specific antidote and further treatment if necessary should be symptomatic. Contact your physician or local Poison Control Center in ...
[43]
[DOC] AusPAR: Conjugated estrogens / Bazedoxifene acetate
Maximum non-lethal doses were 4000 mg/kg by the oral route (in mice and rats) [highest dose tested]; ≤2000 mg/kg (mice) and <500 mg/kg (rats) with IP ...
[44]
Conjugated estrogens: Uses, Interactions, Mechanism of Action
Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.
[45]
The effects of conjugated estrogens on gonadotropins - PubMed
After 1 month of therapy, follicle stimulating hormone (FSH) declined significantly (P . ... Luteinizing hormone (LH) declined by 41% (P .01) after 1 month of ...Missing: antigonadotropic | Show results with:antigonadotropic
[46]
Estrogen and the Skeleton - PMC - PubMed Central - NIH
May 16, 2012 · Estrogen inhibits the activation of bone remodeling, and this effect is most likely mediated via the osteocyte. Estrogen also inhibits bone ...
[47]
VASCULAR ACTIONS OF ESTROGENS: FUNCTIONAL ...
A plethora of studies in humans have clearly demonstrated that estrogen promotes vasodilation through an eNOS-dependent mechanism (Miller and Mulvagh, 2007).
[48]
Pharmacokinetic and pharmacologic variation between ... - PubMed
The terminal half lives for the different estrogen compounds (after oral or intravenous administration) vary from 1-12 hours. Some conversion rates have been ...
[49]
Pharmacokinetic and Pharmacologic Variation Between Different ...
The terminal half lives for the different estrogen compounds (after oral or intravenous administration) vary from 1–12 hours. Some conversion rates have been ...
[50]
Pharmacokinetics and pharmacodynamics of conjugated equine ...
The pharmacokinetics of these estrogens indicate that the unconjugated estrogens are cleared from the circulation at a faster rate than their sulfate ester ...
[51]
Differences in pharmacokinetics and comparative bioavailability ...
... pharmacokinetics and relative bioavailability of the estrogens in Estratab® (esterified estrogens) with those in Premarin® (conjugated estrogens). Twenty ...
[52]
[PDF] Draft Guidance on Conjugated Estrogens - accessdata.fda.gov
components (sodium estrone sulfate and sodium equilin sulfate) and their relative ratio in the ... List of steroidal components in the Conjugated Estrogens USP ...
[53]
Are all estrogens the same? - ScienceDirect.com
Conjugated equine estrogens (CEE) are a mixture of naturally occurring estrogens and contain estrone sulfate and equilin sulfate as the main constituents.
[54]
implications for conjugated equine estrogen components of premarin
NCI 122 has chemical properties, including an unsaturated B-ring and 17alpha-hydroxyl group, which are shared with some of the estrogens found in CEEs.
[55]
NAERIC - North American Equine Ranching Council Foals PMU ...
Estrogens extracted from pregnant mares' urine (PMU) are used in production of hormone therapies for menopausal women. NAERIC serves its members, the horse ...
[56]
A Brief Account of the Discovery of the Fetal/Placental Unit for ... - NIH
Sep 25, 2017 · A notable exception was the “harvest” of estrogens from the urine of pregnant mares in the production of a commercially successful drug, ...
[57]
Method for obtaining estrogens from pregnant mare urine by solid ...
A method for obtaining an extract from urine of pregnant mares containing a natural mixture of conjugated estrogens by solid-phase extraction of the mixture ...
[58]
US20040072812A1 - Process for isolating conjugated estrogens
The present invention relates to a process for extracting conjugated estrogens from pregnant mare urine. The present invention further relates to a process ...
[59]
[PDF] Trends Special Edition_Wyeth Case.indd - Faegre Drinker
In the 1940's and 1950's,. Wyeth obtained patents on several methods discovered in connection with its estrogen extraction research. The last patent, the '712 ...
[60]
Premarin - an overview | ScienceDirect Topics
Premarin is defined as a commercially successful pharmaceutical preparation consisting of a naturally occurring mixture of estrogens derived from equine urine, ...
[61]
Premarin: the intriguing history of a controverisal drug - PubMed
The name Premarin was coined from pregnant mare urine, from which the estrogen complex was isolated. Although the complete composition of Premarin and its ...
[62]
Edgar Allen and Edward A. Doisy's Extraction of Estrogen from ...
Mar 2, 2017 · Allen and Doisy's 1923 experiment to isolate estrogen showed that estrogen is made within the ovaries and also established a method for ...
[63]
History of Estrogen: Its Purification, Structure, Synthesis, Biologic ...
In 1923, Edgar Allen, a reproductive physiologist, was studying the role of follicular fluids obtained from the ovary of sows on uterine weight, vaginal ...
[64]
Review of the Food and Drug Administration's Handling of Issues ...
May 16, 1997 · This report provides the results of our review of the Food and Drug Administration's (FDA) handling of issues related to conjugated estrogens (Premarin).
[65]
Pfizer Inc. Affirms Confidence In Its Hormone Therapy Medicines As ...
Dec 12, 2009 · After the WHI study, Wyeth proactively updated its label and worked with the FDA ... Premarin label seven months before the FDA issued ...
[66]
Drug Approval Package: Premarin (Conjugated Estrogens) NDA ...
Apr 4, 2002 · Premarin (Conjugated Estrogens) Tablets Company: Wyeth Pharmaceuticals Application No.: 21417. Approval Date: 7/16/2003 ; Application No. · 21417
[67]
The History of Menopausal Hormone Therapy (MHT)
1997: Premarin sales exceed $1 billion. 2000: Premarin prescriptions reach 46 million – the most frequently prescribed drug on the market. 2001: Premarin ...
[68]
History of Estrogen, HRT to Treat Menopause Symptoms - AARP
Jul 25, 2018 · In 1992, Premarin became the best-selling drug in the country, and it maintained its popularity through the end of the century, with about a ...
[69]
Reappraising 21 years of the WHI study: Putting the findings in ...
May 11, 2023 · 4 Effect of WHI: changes in MHT prescribing Following the publication of the WHI results in 2002, MHT use fell from 29 % in 2001 to 10–11 % in ...
[70]
Influence of the dramatic fall of hormone replacement therapy (HRT ...
May 20, 2009 · Results: HRT prescription slightly increased from 1998 to 2000, but dramatically decreased by 70% after 2003, reaching a significantly lower ...
[71]
Rethinking Menopausal Hormone Therapy: For Whom, What, When ...
Feb 14, 2024 · A subgroup analysis based on HT timing found that those who initiated HT within 10 years after menopause had lower mortality (RR 0.70, 95% CI ...
[72]
The 2022 hormone therapy position statement of The North ...
Jul 1, 2022 · Hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause and has been shown to prevent ...
[73]
The 2022 hormone therapy position statement of The ... - Menopause
Some studies have suggested that initiating hormone therapy in symptomatic women within 10 years of menopause may have benefit in reduction of atherosclerosis ...
[74]
Risks and Benefits of Estrogen Plus Progestin in Healthy ...
Jul 17, 2002 · Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized ...
[75]
Risks and benefits of estrogen plus progestin in healthy ... - PubMed
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
[76]
A critique of the Women's Health Initiative hormone therapy study
The resultant data indicated that after 5.2 years on the CEE/MPA combination, 10,000 women would have 8 more cases of breast cancer, 8 more strokes, 8 more ...<|separator|>
[77]
The Women's Health Initiative 2004 - Review and Critique - PMC
[4] The smaller hormone study involved 10,739 women who had undergone hysterectomy; they were randomized to receive estrogen alone (0.625 CEE, Premarin) or ...
[78]
A Reappraisal of Women's Health Initiative Estrogen-Alone Trial - NIH
The Women's Health Initiative (WHI) Estrogen-Alone Trial randomized postmenopausal women, 50 to 79 years of age, with prior hysterectomy, to conjugated ...
[79]
Where Are We 10 Years After the Women's Health Initiative?
It has been argued that in the 10 years since WHI, many women have been denied HT, including those with severe symptoms, and that this has significantly ...
[80]
From discovery to debate: The history of menopausal hormone ...
However, there have been multiple trials since the WHI that have shown that HT is indeed safe and effective in treating menopausal symptoms, but may also ...
[81]
The Women's Health Initiative Hormone Therapy Trials - NIH
Overall, the WHI findings suggest that HT has a harmful effect on CHD risk in older women, while the results in younger women remain inconclusive. Lower ...
[82]
A critique of the Women's Health Initiative hormone therapy study
This review critiques The Women's Health Initiative (WHI) study, focusing on aspects of the study design contributing to the adverse events resulting in the ...
[83]
What the Women's Health Initiative has taught us about menopausal ...
This review aims to summarize current knowledge about MHT and CVD risk as a result of the WHI trial and related studies.
[84]
Menopausal Hormone Therapy and Long-term All-Cause and ...
Sep 12, 2017 · The CEE plus MPA trial was stopped early (after 5.6 years) due to an increased risk of breast cancer and overall risks exceeding benefits; the ...
[85]
Review article Reappraising 21 years of the WHI study
4. Effect of WHI: changes in MHT prescribing. Following the publication of the WHI results in 2002, MHT use fell from 29 % in 2001 to 10–11 % in 2005 among ...
[86]
[PDF] Code of Practice - Horses on PMU Ranches - NAERIC
The Code of Practice for the Care. & Handling of Horses on PMU Ranches provides additional requirements and recommendations specific to the Pregnant Mares Urine ...
[87]
Position on the Management of Mares Utilized in the Pregnant Mare ...
The American Association of Equine Practitioners (AAEP) believes the collection of urine from pregnant mares and care of their offspring as prescribed by the “ ...Missing: farms animal standards
[88]
[PDF] Care and Oversight of Horses Managed for the Collection ... - NAERIC
The current AAEP Position on the Management of Mares Utilized in the Pregnant Mare. Urine (PMU) Collection Industry (2010) states “Through on-site ...
[89]
Past concerns for Foal Welfare | Pregnant Mares' Urine (PMU) Industry
At industry peak, estimates suggest this number may have been upwards of 40,000 to 50,000 foals a year from US and Canada and colts are more likely to be sent ...
[90]
Pfizer Ordered to Pay $34.3 Million in HRT Lawsuit | MedPage Today
Nov 24, 2009 · A Philadelphia jury ordered Pfizer to pay $28 million in punitive damages, and $6.3 million in compensatory damages to a breast cancer survivor.
[91]
Court Awards over $13M in Premarin Lawsuit - All-Creatures.org
A large portion of that settlement, about 43 per cent, will go to legal counsel for the plaintiffs in the class action suit. The approximately 1,100 plaintiffs ...Missing: WHI | Show results with:WHI
[92]
California Premarin Class Action Settlement
May 4, 2020 · California residents who purchased Premarin hormone replacement therapy drugs, could get cash from a $200 million class action settlement.
[93]
Premarin Class Action Settlement - Community Catalyst
Jul 19, 2007 · The Defendants have agreed to pay $5.2 million to settle this case. After deductions of Court-approved costs and expenses, the remaining amount ...
[94]
Estrogen formulations get FDA "black-box" warning - Medscape
Jan 8, 2003 · The Women's Health Initiative (WHI) reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and ...
[95]
FDA Expert Panel on Menopause and Hormone Replacement ...
Jul 17, 2025 · The panel focused on the risks and benefits of menopause hormone therapy, and in particular, the risks of breast cancer, uterine cancer, and ...Missing: 2020s conjugated
[96]
https://www.medscape.com/viewarticle/fda-panel-urges-review-boxed-warning-menopause-therapy-2025a1000swh
[97]
The black box warning on menopause treatments could change ...
Oct 7, 2025 · Currently, the black box warning on estrogen warns of endometrial cancer, cardiovascular disorders, probable dementia and breast cancer. How is ...Missing: conjugated | Show results with:conjugated
[98]
European Code against Cancer 4th Edition: Medical exposures ...
The 4th edition of the European Code against Cancer recommends limiting – or avoiding when possible – the use of hormone replacement therapy (HRT) because ...
[99]
European and North American Experience with HRT for ... - PubMed
In the United States, HRT formulations traditionally comprise conjugated equine estrogens. In Europe, however, HRT preparations tend to be based on 17 beta ...Missing: regulations | Show results with:regulations
[100]
Menopause and HRT – the state of the art in Europe - ScienceDirect
The HRT field has been dramatically affected by the publication on major randomised controlled trials of the long-term effects of HRT.
[101]
Conjugated estrogens (oral route) - Side effects & dosage
Aug 31, 2025 · It is used to treat moderate to severe hot flashes, changes in and around the vagina, and other symptoms of menopause or low amounts of estrogen ...Missing: evidence- | Show results with:evidence-
[102]
Premarin (conjugated estrogens) - Uses, Side Effects, and More
Dec 20, 2024 · Overdose/Missed Dose If you or someone else has used too much Premarin, get medical help right away, call 911, or contact a Poison Control ...
[103]
Conjugated estrogens Uses, Side Effects & Warnings - Drugs.com
Feb 28, 2025 · Conjugated estrogens may cause serious side effects. Call your doctor at once if you have: heart attack symptoms--chest pain or pressure, pain ...Missing: management | Show results with:management
[104]
Generic Premarin Availability - Drugs.com
Oct 8, 2025 · Manufacturer: WYETH PHARMS Approval date: January 26, 1984. Strength(s): 0.9MG; Manufacturer: WYETH PHARMS Approval date: July 16, 2003
[105]
https://www.drugpatentwatch.com/blog/how-premarin-maintained-market-dominance-without-patent-protection/
[106]
Conjugated Estrogen - an overview | ScienceDirect Topics
Conjugated estrogen refers to estrogens that are chemically altered by the addition of sulfate groups, which decreases their binding affinity to estrogen ...Missing: toxicity | Show results with:toxicity
[107]
https://www.goodrx.com/premarin
[108]
https://www.goodrx.com/premarin-vaginal-cream
[109]
[PDF] Safety and Efficacy of Bioidentical Hormone Therapy in Menopause
Apr 14, 2021 · Conjugated equine estrogen (CEE) is derived from female horse urine and does not require any chemical synthesis, however it is considered a ...
[110]
A comparative characterization of estrogens used in hormone ...
Taken together, the results indicating that there is mostly no difference between the custom-compounded bioidentical estrogens, commercially available estrogen ...
[111]
Menopausal Hormone Therapy and Risk for Venous ...
Jan 17, 2019 · Direct comparison of oral estradiol versus CEE showed that VTE risk with oral estradiol was statistically significantly lower (OR, 0.85). In ...
[112]
Postmenopausal Estrogen Therapy Route of Administration ... - ACOG
The relative risk seems to be even greater if the treated population has preexisting risk factors for venous thromboembolism, such as obesity, immobilization, ...
[113]
Menopausal hormone therapy and breast cancer risk: 21 years from ...
Nov 5, 2024 · This article analyzes relevant studies that associate the relative risk of suffering from breast cancer with the use of menopausal hormone therapy.
[114]
Compounded Bioidentical Hormones in Endocrinology Practice
Overall, there is a general lack of standardization and quality control regarding how custom-compounded bioidentical hormones are produced and administered, ...
[115]
Compounded Bioidentical Menopausal Hormone Therapy - ACOG
This document focuses specifically on the use of compounded bioidentical menopausal hormone therapy, not compounding for other evidence-based reasons.
[116]
The dangers of compounded bioidentical hormone replacement ...
This can lead to an increased risk of venous thromboembolism, as well as increasing the risk of endometrial cancer.
[117]
[PDF] 2022 Hormone Therapy Position Statement - The Menopause Society
In an effort to provide the most up-to-date, scientifically based information on the topic, The North American Menopause Society (NAMS) has issued its 2022 ...
[118]
Bioidentical hormones: Are they safer? - Mayo Clinic
Are bioidentical or natural hormones safer and more effective than hormones used in traditional hormone therapy for menopause symptoms? No, they aren't.